Answers are grounded in this paper and cite their sources.
Surveys reveal variability in care for relapsed/refractory multiple myeloma in China, suggesting the need for better guidelines.
Real-world management of relapsed/refractory MM in China is highly variable. These findings highlight the necessity for ongoing research and evidence-based guidelines to optimize patient outcomes.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: